It’s no secret that Barbara Borden—the 13th most active dealmaker of all time for publicly disclosed deals, according to Deal Point Data—has led some of the largest life sciences and health care deals in the past decade. But a groundbreaking exit for legacy client Horizon Therapeutics last year just might take the cake, according to the Cooley partner.

“It was a career deal for me,” Borden said. “Horizon was such an important client to me personally … it’s bittersweet. I’ll miss them, but I’m happy for the great outcome.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]